Potential Risks Associated with the Use of Herbal Anti-Obesity Products
- 137 Downloads
The public wants an easy way to control obesity. Herbal anti-obesity products attract users because of their health claims, assumed safety, easy availability and extensive marketing. These products can be very heterogeneous in nature and have unpredictable levels of active ingredients, and unpredictable and potentially harmful effects. They may contain highly toxic herbs (e.g. Aristolochia species), potent herbs not recommended for use in weight control (e.g. Ephedra sinica) and herbal laxatives with potential hepatotoxic and nephrotoxic effects (e.g. anthraquinones). However, the presence of such herbs may not be disclosed on the product label. They may contain adulterants (e.g. drugs, drug analogues and thyroid extracts), including drugs that have been withdrawn from the market (e.g. fenfluramine). For all these reasons, herbal anti-obesity products can cause direct toxicity or adverse interactions with concurrent medications. Physicians and other healthcare professionals need to be aware of the problem. They should warn their patients about the heterogeneous nature of these agents and the potential risks associated with their use. They should report suspected adverse reactions to their national spontaneous reporting system.
KeywordsAnthraquinone Sibutramine Fenfluramine Herbal Product Health Claim
No funding was received for the preparation of this review and the author has no potential conflicts of interest to declare.
- 7.National Heart, Lung, and Blood Institute and North American Association for the Study of Obesity. NHLBI obesity education initiative: practical guide to the identification, evaluation and treatment of overweight and obesity in adults. Bethesda (MD): National Institutes of Health, 2000. NIH publication number 98–4084Google Scholar
- 8.Poon WT, Mak TWL, Chan AYW. Slimming agent-related adversities in Hong Kong. Poisoning Comm 2007; 2(2): 1–2 [online]. Available from URL: http://www.chp.gov.hk/files/pdf/grp-poison-en-20070430.pdf [Accessed 2009 Mar 12]Google Scholar
- 11.Wong A, Chan C. Review of adverse events related to Chinese medicines in Hong Kong, July 2004–June 2005. Public Health Epidemiol Bull 2005; 14: 45–51Google Scholar
- 23.Hong Kong Consumer Council. A detailed analysis on proprietary cleansing and slimming products. Choice Mag 2001; 301: 12–23Google Scholar
- 24.European Medicines Agency. Assessment report for rhubarb (Rhei radix). London: EMA, 2008 [online]. Available from URL: http://www.emea.europa.eu/pdfs/human/hmpc/rhei_radix/18962607en.pdf [Accessed 2009 Mar 12]
- 30.Chang K, Mak TWL, Kwong L, et al. Valvular heart disease caused by Chinese proprietary slimming medicine adulterated with fenfluramine. Hong Kong J Paediatr 2005; 10: 55–8Google Scholar
- 36.Anonymous. Thyroid extracts as slimming aids: danger! [editorial]. Prescrire Int 2006; 15: 183Google Scholar